Instrument name
ISIN code
LEI code
Exchange / Market
Trading location
Products family
Capitalization compartment
Compartment B
20103015 Pharmaceuticals
IPO date
IPO type
Initial Public offering
Price range
EUR 10.00 - EUR 11.50 (inclusive)

Company profile

Hyloris Pharmaceuticals SA specializes in the development and reformulation of existing pharmaceutical products, with a focus on cardiovascular diseases. The company has 2 early stage commercial products : Sotalol IV for the treatment of atrial fibrillation developed in partnership with AltaThera (of which the commercialization in the United States is expected for Q3 2020), and Maxigesic® IV for the treatment of pain co-owned with AFT Pharmaceuticals (of which a number of approvals by European regulatory authorities are expected throughout H2 2020, and the approval by the U.S. FDA is expected for H2 2021, with commercialization in such jurisdictions expected after such approvals). Hyloris Pharmaceuticals SA also operates a portfolio of 12 products (of which 4 are in the cardiovascular space) in various stages of development.

Source: Cofisem - Last Update: 31 Aug 2020
Key figures
Millenium 2019 2018 2017
Net sales 91 91 213
Income from ordinary activities 91 91 213
Operating income -5,274 -5,469 -3,866
Cost of financial indebtedness net -415 -339 -146
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -5,768 -6,038 -3,717
Net income (Group share) -5,373 -5,791 -3,717
Fiscal year end 12.19 12.18 12.17
Length of fiscal year (month) 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 31 Aug 2020
Shareholder information
Source: Cofisem - Last Update: 31 Aug 2020